
Hereditary Testing Market by Disease Type (Hereditary Cancer Testing, Hereditary Non-Cancer Testing, Newborn Genetic Screening), Technology (Biochemical, Cytogenetic, Molecular Testing), Application, End-User - Global Forecast 2024-2030
Description
Hereditary Testing Market by Disease Type (Hereditary Cancer Testing, Hereditary Non-Cancer Testing, Newborn Genetic Screening), Technology (Biochemical, Cytogenetic, Molecular Testing), Application, End-User - Global Forecast 2024-2030
The Hereditary Testing Market size was estimated at USD 5.15 billion in 2023 and expected to reach USD 5.57 billion in 2024, at a CAGR 8.17% to reach USD 8.93 billion by 2030.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Hereditary Testing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Hereditary Testing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Hereditary Testing Market, highlighting leading vendors and their innovative profiles. These include BGI Genomics Co., Ltd., Biocartis NV, CENTOGENE N.V., CooperSurgical, Inc., CSL Behring, Eurofins Scientific SE, F. Hoffmann-La Roche Ltd., Invitae Corporation, Konica Minolta, Inc., Medgenome, Myriad Genetics, Inc., Natera Inc., Quest Diagnostics Incorporated, Siemens Healthineers AG, and SOPHiA Genetics.
Market Segmentation & Coverage
This research report categorizes the Hereditary Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:
Disease Type
Hereditary Cancer Testing
Breast Cancer
Cervical Cancer
Colorectal Cancer
Lung Cancer
Melanoma
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Sarcoma
Stomach or Gastric Cancer
Uterine Cancer
Hereditary Non-Cancer Testing
Genetic Tests
Cardiac Diseases
Rare Diseases
Newborn Genetic Screening
Non-Invasive Prenatal Testing & Carrier Screening Tests
Preimplantation Genetic Diagnosis & Screening
Technology
Biochemical
Cytogenetic
Molecular Testing
Application
Cancer Diagnosis
Cardiovascular Disease Diagnosis
Genetic Disease Diagnosis
End-User
Clinics
Hospitals
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom
The report offers valuable insights on the following aspects:
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
1. What is the market size and forecast of the Hereditary Testing Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Hereditary Testing Market?
3. What are the technology trends and regulatory frameworks in the Hereditary Testing Market?
4. What is the market share of the leading vendors in the Hereditary Testing Market?
5. Which modes and strategic moves are suitable for entering the Hereditary Testing Market?
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
199 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Hereditary Testing Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Exploration for changes or variants, in DNA to find root cause of potential disease
- 5.1.1.2. Increased screening by pregnant women
- 5.1.1.3. Rising R&D activities on advance Genome sequencing
- 5.1.2. Restraints
- 5.1.2.1. Limited reimbursement policies
- 5.1.3. Opportunities
- 5.1.3.1. Collaborative product development
- 5.1.3.2. Attractive investment and amalgamation activity within value chain
- 5.1.4. Challenges
- 5.1.4.1. Uncertain outcomes of the hereditary testing
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Hereditary Testing Market, by Disease Type
- 6.1. Introduction
- 6.2. Hereditary Cancer Testing
- 6.3.1. Breast Cancer
- 6.3.2. Cervical Cancer
- 6.3.3. Colorectal Cancer
- 6.3.4. Lung Cancer
- 6.3.5. Melanoma
- 6.3.6. Ovarian Cancer
- 6.3.7. Pancreatic Cancer
- 6.3.8. Prostate Cancer
- 6.3.9. Sarcoma
- 6.3.10. Stomach or Gastric Cancer
- 6.3.11. Uterine Cancer
- 6.3. Hereditary Non-Cancer Testing
- 6.4.1. Genetic Tests
- 6.4.2.1. Cardiac Diseases
- 6.4.2.2. Rare Diseases
- 6.4. Newborn Genetic Screening
- 6.5. Non-Invasive Prenatal Testing & Carrier Screening Tests
- 6.6. Preimplantation Genetic Diagnosis & Screening
- 7. Hereditary Testing Market, by Technology
- 7.1. Introduction
- 7.2. Biochemical
- 7.3. Cytogenetic
- 7.4. Molecular Testing
- 8. Hereditary Testing Market, by Application
- 8.1. Introduction
- 8.2. Cancer Diagnosis
- 8.3. Cardiovascular Disease Diagnosis
- 8.4. Genetic Disease Diagnosis
- 9. Hereditary Testing Market, by End-User
- 9.1. Introduction
- 9.2. Clinics
- 9.3. Hospitals
- 10. Americas Hereditary Testing Market
- 10.1. Introduction
- 10.2. Argentina
- 10.3. Brazil
- 10.4. Canada
- 10.5. Mexico
- 10.6. United States
- 11. Asia-Pacific Hereditary Testing Market
- 11.1. Introduction
- 11.2. Australia
- 11.3. China
- 11.4. India
- 11.5. Indonesia
- 11.6. Japan
- 11.7. Malaysia
- 11.8. Philippines
- 11.9. Singapore
- 11.10. South Korea
- 11.11. Taiwan
- 11.12. Thailand
- 11.13. Vietnam
- 12. Europe, Middle East & Africa Hereditary Testing Market
- 12.1. Introduction
- 12.2. Denmark
- 12.3. Egypt
- 12.4. Finland
- 12.5. France
- 12.6. Germany
- 12.7. Israel
- 12.8. Italy
- 12.9. Netherlands
- 12.10. Nigeria
- 12.11. Norway
- 12.12. Poland
- 12.13. Qatar
- 12.14. Russia
- 12.15. Saudi Arabia
- 12.16. South Africa
- 12.17. Spain
- 12.18. Sweden
- 12.19. Switzerland
- 12.20. Turkey
- 12.21. United Arab Emirates
- 12.22. United Kingdom
- 13. Competitive Landscape
- 13.1. FPNV Positioning Matrix
- 13.2. Market Share Analysis, By Key Player
- 13.3. Competitive Scenario Analysis, By Key Player
- 14. Competitive Portfolio
- 14.1. Key Company Profiles
- 14.1.1. BGI Genomics Co., Ltd.
- 14.1.2. Biocartis NV
- 14.1.3. CENTOGENE N.V.
- 14.1.4. CooperSurgical, Inc.
- 14.1.5. CSL Behring
- 14.1.6. Eurofins Scientific SE
- 14.1.7. F. Hoffmann-La Roche Ltd.
- 14.1.8. Invitae Corporation
- 14.1.9. Konica Minolta, Inc.
- 14.1.10. Medgenome
- 14.1.11. Myriad Genetics, Inc.
- 14.1.12. Natera Inc.
- 14.1.13. Quest Diagnostics Incorporated
- 14.1.14. Siemens Healthineers AG
- 14.1.15. SOPHiA Genetics
- 14.2. Key Product Portfolio
- 15. Appendix
- 15.1. Discussion Guide
- 15.2. License & Pricing
- FIGURE 1. HEREDITARY TESTING MARKET RESEARCH PROCESS
- FIGURE 2. HEREDITARY TESTING MARKET SIZE, 2023 VS 2030
- FIGURE 3. HEREDITARY TESTING MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. HEREDITARY TESTING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. HEREDITARY TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. HEREDITARY TESTING MARKET DYNAMICS
- FIGURE 7. HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
- FIGURE 8. HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
- FIGURE 10. HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
- FIGURE 12. HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. HEREDITARY TESTING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
- FIGURE 14. HEREDITARY TESTING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. AMERICAS HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 16. AMERICAS HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 18. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 20. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 22. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 23. HEREDITARY TESTING MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 24. HEREDITARY TESTING MARKET SHARE, BY KEY PLAYER, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.